RxDoctor Payments Data

Ana Abaroa-Salvatierra, MD

Internal Medicine · Pollocksville, NCNPI 1598101750

Payments from drug & device makers

$4,941in general payments, 2019–2025

Across 282 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$772
  • Amgen$769
  • Boehringer Ingelheim$525
  • Novo Nordisk$506
  • Bayer$410
  • AstraZeneca$400
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,934100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,941 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$208,422
Medicare patients
244
Services billed
13,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide99$123,303
JardianceEmpagliflozin118$118,990
OzempicSemaglutide91$108,961
FarxigaDapagliflozin Propanediol52$53,612
EliquisApixaban46$48,030
XareltoRivaroxaban35$36,566
Soliqua 100-33Insulin Glargine/Lixisenatide25$24,725
TradjentaLinagliptin41$22,539
Bydureon BciseExenatide Microspheres22$22,084
Repatha SureclickEvolocumab27$18,889
JanuviaSitagliptin Phosphate16$16,919
RybelsusSemaglutide15$14,206
Tresiba Flextouch U-100Insulin Degludec33$13,628
EntrestoSacubitril/Valsartan17$13,096
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$11,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$525$141,529159 claims
Lilly USA, LLCTrulicity$328$123,30399 claims
Novo NordiskOzempic, Rybelsus$506$123,168106 claims
AstraZenecaFarxiga, Symbicort$400$60,93683 claims
PfizerEliquis$102$48,03046 claims
Johnson & JohnsonXarelto$28$36,56635 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$364$24,72525 claims
MerckJanuvia$18$16,91916 claims
NovartisEntresto$18$13,09617 claims
AbbVieLinzess$772$11,32212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Pollocksville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →